Aileron therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Aileron therapeutics Contact Number

Home Aileron

6 hours ago Aileronrx.com Show details

(617) 995-0900

Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients. Learn More. ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects.

1. 490 Arsenal St, Watertown, MA 02472 · (617) 995-0900DIRECTIONSWEBSITE

Category: Home PhoneShow more

Aileron Therapeutics Crunchbase

Just Now Crunchbase.com Show details

Contact Email [email protected] Phone Number (617)995-0900 Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides.

Founded: 2005
Founder: Rosana Kapeller

Category: Contact NumberShow more

FAQs ― Aileron Therapeutics

9 hours ago Investors.aileronrx.com Show details

617-995-0900

Aileron’s headquarters are located at 490 Arsenal Way, Watertown, MA 02472. The main office number is 617-995-0900.

Category: Contact NumberShow more

About Us Aileron

7 hours ago Aileronrx.com Show details

At Aileron, we are focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple

Category: Contact NumberShow more

FORM D SEC

4 hours ago Sec.gov Show details

617-995-0900

Principal Place of Business and Contact Information. Name of Issuer; AILERON THERAPEUTICS INC: Street Address 1 Street Address 2; 840 MEMORIAL DRIVE: 2ND FLOOR: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MA: 02139: 617-995-0900: 3. Related Persons. Last Name First Name Middle Name; Yanchik III: Joseph: A

Category: Contact NumberShow more

AILERON THERAPEUTICS INC (Form: S1/A EDGAR Online

3 hours ago Content.edgar-online.com Show details

(617) 995-0900

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Joseph A. Yanchik III President and Chief Executive Officer Aileron Therapeutics, Inc. 281 Albany Street Cambridge, MA 02139 (617) 995-0900

Category: Contact NumberShow more

Safety Study of ALRN6924 in Patients ClinicalTrials.gov

7 hours ago Clinicaltrials.gov Show details

Number of participants with treatment-related adverse events as assessed by CTCAE v.4.0. you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Aileron Therapeutics, Inc. More Information.

Category: Contact NumberShow more

Aileron Grow a Thriving Business with Aileron's DOC System

4 hours ago Aileron.org Show details

Aileron's DOC System is a proven approach to running a thriving business that has empowered thousands of leaders to transform their businesses Our community knows that a professionally-managed business can raise the quality of life for business owners, …

Category: Contact NumberShow more

AILERON THERAPEUTICS INC (Form: DEF 14A EDGAR Online

5 hours ago Content.edgar-online.com Show details

A copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission, or SEC, except for exhibits, will be furnished without charge to any stockholder upon written or oral request to Aileron Therapeutics, Inc., 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472 or by

Category: Contact NumberShow more

Investors & Media ― Aileron Therapeutics

2 hours ago Investors.aileronrx.com Show details

617-995-0900

Aileron Therapeautics, Inc. 285 Summer Street, Suite 101 Boston, MA 02210 Phone: 617-995-0900 Fax: 617-995-2410 Email: [email protected]

Category: Contact NumberShow more

Team APIE

5 hours ago Apie-therapeutics.com Show details

Meet The Team. Together, we share a mission to provide therapeutic solutions that extend patients’ lives. Our team is highly experienced and well-positioned to deliver first-in-class therapies. We have partnered with top academic researchers, practicing medical professionals and institutions to …

Category: Contact NumberShow more

These Numbers Show Just How Powerful Aileron Therapeutics

1 hours ago Stocksregister.com Show details

Aileron Therapeutics Inc., which has a market valuation of $107.80 million, is expected to release its quarterly earnings report Nov 10, 2021 – Nov 15, 2021. Analysts tracking ALRN have forecast the quarterly EPS to shrink by -0.07 per share this quarter, while the same analysts predict the annual EPS to hit -$0.3 for the year 2021 and up to

Category: Contact NumberShow more

ALRN Aileron Therapeutics Inc. BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

About Aileron Therapeutics. Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle.

Category: Contact NumberShow more

Who We Are Aileron

5 hours ago Aileron.org Show details

(937) 669-6500

Facility Specialist. (937) 669-6500. It’s a privilege to work at Aileron as a Facility Specialist who is responsible for supporting day-to-day campus operations and sponsored events. I ensure the needs of staff and external clients are met through supporting the client’s needs and helping them to …

Category: Contact NumberShow more

Contact Us Acer Therapeutics

9 hours ago Acertx.com Show details

(844) 902-6100

Acer – Bend Office. 1000 NW Wall Street, Suite 220. Bend, OR 97703. (844) 902-6100. From Redmond Airport: Take US-97 South to Exit 137 for Revere Ave toward Downtown. Continue straight onto NW Wall Street. Our building, 1000 NW Wall Street, is located on the left. We are in Suite 220, above Patagonia.

Category: Contact SupportShow more

Aileron Therapeutics Crunchbase

9 hours ago Crunchbase.com Show details

Aileron Therapeutics has raised a total of $218.2M in funding over 10 rounds. Their latest funding was raised on Jan 6, 2021 from a Post-IPO Secondary round. Aileron Therapeutics is registered under the ticker NASDAQ:ALRN . Their stock opened with $15.00 in its Jun 29, 2017 IPO. Aileron Therapeutics is funded by 14 investors.

Category: Contact NumberShow more

Aileron Therapeutics, Inc. (ALRN) Stock Analysis

6 hours ago Stockanalysis.com Show details

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); …

Category: Contact NumberShow more

Aileron Therapeutics How Have the Numbers Shaped Up for

7 hours ago Stockmarketdaily.co Show details

Only 4.90% of the stock of Aileron Therapeutics is held by insiders. Only 37.01% of the stock of Aileron Therapeutics is held by institutions. Earnings and Valuation of Aileron Therapeutics (NASDAQ:ALRN. Earnings for Aileron Therapeutics are expected to decrease in the coming year, from ($0.31) to ($0.38) per share.

Category: Contact NumberShow more

Aileron Therapeutics : Presents New Clinical Data at ESMO

Just Now Marketscreener.com Show details

617-995-0900

Aileron Therapeutics 617-995-0900 [email protected] : Media Contact: Liz Melone 617-256-6622 [email protected] : Hans C. Vitzthum LifeSci Advisors, LLC. 617-430-7578 [email protected]

Category: Contact NumberShow more

Aileron Therapeutics Company Profile Craft

7 hours ago Craft.co Show details

Aileron Therapeutics is a clinical-stage biopharmaceutical company. The Company's lead product candidate, ALRN-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins MDMX and MDM2.

Category: Contact NumberShow more

ALRN SEC Filings Aileron Therapeutics Inc 10K and 10Q

Just Now Fintel.io Show details

017-08-10

2017-08-10. 10-Q. ALRN / Aileron Therapeutics Inc. FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR

Category: Contact NumberShow more

Aileron Therapeutics Announces $35.9 Million Yahoo

1 hours ago Finance.yahoo.com Show details

WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors

Category: Contact NumberShow more

SRO List Detail

6 hours ago Accessdata.fda.gov Show details

888-463-6332

10903 New Hampshire Avenue Silver Spring, MD 20993 Ph. 1-888-INFO-FDA (1-888-463-6332) Contact FDA

Category: Contact NumberShow more

Aileron Therapeutics Inc (ALRN) Quote Morningstar, Inc.

Just Now Morningstar.com Show details

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. Contact 290

Category: Contact NumberShow more

AILERON THERAPEUTICS INC : Other Events (form 8K

8 hours ago Marketscreener.com Show details

Item 8.01 Other Events. On September 16, 2021, Aileron Therapeutics, Inc. (the "Company" or "Aileron") announced final results from its Phase 1b trial of ALRN-6924 in patients with small cell lung cancer ("SCLC") receiving second-line topotecan. The Company also announced preliminary results from its ongoing Phase 1 pharmacology study of ALRN-6924 in healthy volunteers.

Category: Contact NumberShow more

Aileron Therapeutics Presents Data at AACRNCIEORTC

5 hours ago Finance.yahoo.com Show details

BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer

Category: Contact NumberShow more

Aileron Therapeutics Inc (ALRN) 10K Annual Last10K.com

6 hours ago Last10k.com Show details

Inside Aileron Therapeutics Inc's 10-K Annual Report: Revenue - Product Highlight To date, we have financed our operations primary through $50.0 million in net proceeds from our initial public offering, or IPO, $23.8 million in net proceeds from a private placement in April 2019, $10.2 million in net proceeds from a public offering in June 2020, $33.1 million in net proceeds from a registered

Category: Contact NumberShow more

Aileron Therapeutics Inc. (ALRN): The stock short term

Just Now Baxterreport.com Show details

The total number of common shares currently owned by the public is 90.46 million. ALRN does have institutional investors; and they hold 38.30% of the stock. Aileron Therapeutics Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Category: Contact NumberShow more

Aileron Therapeutics Inc. (NASDAQ: ALRN) Down 6.77% YTD

5 hours ago Marketingsentinel.com Show details

Aileron Therapeutics Inc. (NASDAQ:ALRN)’s traded shares stood at 0.53 million during the last session, with the company’s beta value hitting 2.70. At the close of trading, the stock’s price was $0.97, to imply a decrease of -2.99% or -$0.03 in intraday trading. The ALRN share’s 52-week high

Category: Contact NumberShow more

SRO List Food and Drug Administration

3 hours ago Accessdata.fda.gov Show details

SRO List. You can search the list by entering the DUNS NUMBER, BUSINESS NAME, or TICKER SYMBOL in the search criteria. The SRO list is a comprehensive and important resource to check regularly, however, it is not definitive. There are some situations where a financial interest may constitute a prohibited financial interest in an SRO, even if it

Category: Contact NumberShow more

Aileron Therapeutics Stock Forecast, Price & News MarketBeat

6 hours ago Marketbeat.com Show details

2 Wall Street analysts have issued twelve-month price targets for Aileron Therapeutics' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Aileron Therapeutics' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 239.8% from the stock's current price.

Category: Contact NumberShow more

Aileron Therapeutics Inc (ALRN) Price Targets StockNews

6 hours ago Stocknews.com Show details

The number of analysts covering the stock of ALRN is greater than 13.06% of Healthcare stocks. In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Aileron Therapeutics Inc are ZSAN , TCRX and AWH .

Category: Contact NumberShow more

Remarkable Stock News Review: Aileron Therapeutics, Inc

8 hours ago Nxtmine.com Show details

Aileron Therapeutics, Inc. (ALRN) with the stream of 3.30% also noticed, India Kinross Gold Corporation (KGC) encountered a rapid change of 1.18% in the last hour of Tuesday’s trading session. Aileron Therapeutics, Inc. (NASDAQ:ALRN) closed at $1.16 and the price was 7.69% so far this year. The price/earnings to growth ratio (PEG ratio) is a stock’s price-to-earnings (P/E) ratio …

Category: Contact NumberShow more

Phase 1 Safety Study of ALRN5281 in ClinicalTrials.gov

7 hours ago Clinicaltrials.gov Show details

The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers. Time to Reach Maximum Observed Plasma Concentration (Tmax) of ALRN-5281 [ Time Frame: Predose, Day 1- 0.5,1,2,3,4,6,8,10,12,14 and 16hr post dose , Day 2-Day11 and Day14

Category: Contact NumberShow more

Noriyuki (Nori) Kawahata Senior Director LinkedIn

Just Now Linkedin.com Show details

Aileron Therapeutics 5 years 7 months managed and refined workflow as the team was tasked with the synthesis and purification of a large number of compounds across different chemical families

Title: Senior Director, Program and …
Location: Cambridge, Massachusetts
1. 500+ connections

Category: Contact NumberShow more

Ubiquitin Enzymes Market Rise in Demand, Future Analysis

7 hours ago Medgadget.com Show details

A number of procedural advances in ubiquitin enzyme had led to the enhancement and development of varied technological platforms, research-based assessment, tool …

Category: Contact NumberShow more

Amended Statement of Ownership (sc 13g/a) ADVFN

6 hours ago Ih.advfn.com Show details

Name of Issuer: Aileron Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 00887A105 *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the

Category: Contact NumberShow more

FORMULATION DEVELOPMENT Bioavailability Drug Dev

4 hours ago Drug-dev.com Show details

Category: Contact NumberShow more

DEF 14A SEC

4 hours ago Sec.gov Show details

We do not know of any matters that may come before the annual meeting other than the election of the Class I directors, the approval of an amendment to our certificate of incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000, the approval of the Aileron Therapeutics, Inc. 2021 Stock Incentive

Category: Contact NumberShow more

Gregory Verdine, PhD Wave Life Sciences

7 hours ago Wavelifesciences.com Show details

He founded a number of successful biotech companies, including Enanta Pharmaceuticals (NASDAQ: ENTA), Gloucester Pharmaceuticals (acquired by Celgene), Tokai Therapeutics (NASDAQ: TKAI), Eleven Biotherapeutics (NASDAQ: EBIO), Wave Life Sciences, Warp Drive Bio, Aileron Therapeutics, and FOG Pharmaceuticals.

Category: Contact NumberShow more

Insider Trading activities at Aileron Insider monitor

5 hours ago Insider-monitor.com Show details

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aileron Therapeutics Inc (ALRN) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aileron Therapeutics Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1420565.

Category: Contact NumberShow more

Aileron Therapeutics 2021 Investment ALRN Macroaxis

7 hours ago Macroaxis.com Show details

Aileron Therapeutics is selling for 1.17 as of the 18th of September 2021. This is a 8.33 percent up since the beginning of the trading day. The stock's open price was 1.08. Get the latest Aileron Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Aileron Stock investment advice, charts, stats and more.

Category: Contact NumberShow more

Study Underway to Test ALRN6924 in p53Mutated Non–Small

7 hours ago Targetedonc.com Show details

1. Aileron Therapeutics announces initiation of randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced non-small cell lung cancer (NSCLC). News release. Aileron Therapeutics. July 1, 2021. Accessed July 1, 2021. https://bit.ly/3jzp55w. 2.

Category: Contact NumberShow more

ALRN Stock Aileron Therapeutics Inc SEC Filings Donuts

Just Now Sec.report Show details

The following company has records linked to the trading symbol ALRN: AMERICAN LEARNING Corp. documents---0.00084495544433594. Aileron Therapeutics Inc is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Aileron Therapeutics Inc is primarely in the business of pharmaceutical preparations.

Category: Contact NumberShow more

Get to Know Our Team Bakx Therapeutics The Aptosis Company

8 hours ago Bakxtx.com Show details

She has extensive experience developing cancer therapeutics, across pharma, biotech, and academia. Prior to BAKX, Jessie was Chief Scientific Officer of Tilos Therapeutics, developing therapeutic antibodies targeting LAP as a novel approach to targeting TGF-beta, till acquisition by Merck in 2019.

Category: Contact NumberShow more

Aileron Therapeutics Announces ProofofConcept Yahoo

3 hours ago Au.finance.yahoo.com Show details

Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.Investor Contacts: Media Contact: Richard Wanstall, SVP Chief Financial Officer Liz Melone

Category: Contact NumberShow more

Should You Buy Aileron Therapeutics Inc (ALRN) Stock

4 hours ago Investorsobserver.com Show details

Aileron Therapeutics Inc has risen 91.35% over the past month, closing at $1.23 on January 6. During this period of time, the stock fell as low as $1.23 and as high as $2.33. ALRN has an average analyst recommendation of Strong Buy. The company has an average price target of $2.00. ALRN has an Overall Score of 70.

Category: Contact NumberShow more

Aileron Therapeutics Presents GuruFocus.com

7 hours ago Gurufocus.com Show details

About Aileron Therapeutics. Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is aileron therapeutics inc?

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases.

How does alrn aileron therapeutics help cancer patients?

Aileron is developing ALRN-6924, a novel chemoprotective medicine, to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects. Chemotherapy preferentially acts on cells that are cycling, i.e. undergoing the process of cell division.

Who are the members of the aileron team?

That’s what drives me – making an impact on people’s lives.” Lindsey Bahr, CPA, MBA, first saw herself working for Aileron when she was a public accountant auditing Aileron, but at the time, she had no idea she’d later be a member of the team.

Which is the best way to get started with aileron?

The best way to get started with Aileron is through the Course for Presidents ®. It’s our introduction to our system for running a thriving business, and it’s designed specifically for presidents, business owners, and CEOs.

Brand New Updated

Popular Brands

Amazon
Abbvie
Aia
Asml
Att
Amgen
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes